|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-9-7
|
|
pubmed:abstractText |
Capecitabine has antitumor activity in metastatic breast cancer (MBC); however, its optimal dose and schedule remain unclear. Mathematical modeling predicts that a capecitabine schedule 7 days of treatment followed by 7 days of rest (7-7) will improve efficacy and minimize toxicity. Bevacizumab has demonstrated the ability to improve outcomes when it is added to chemotherapy, including capecitabine, in the first-line and second-line settings.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-0142
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Cancer Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
117
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4125-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21387266-Adult,
pubmed-meshheading:21387266-Aged,
pubmed-meshheading:21387266-Antibodies, Monoclonal,
pubmed-meshheading:21387266-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21387266-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21387266-Breast Neoplasms,
pubmed-meshheading:21387266-Deoxycytidine,
pubmed-meshheading:21387266-Female,
pubmed-meshheading:21387266-Fluorouracil,
pubmed-meshheading:21387266-Humans,
pubmed-meshheading:21387266-Middle Aged,
pubmed-meshheading:21387266-Neoplasm Metastasis
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
|
|
pubmed:affiliation |
Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
